Pozen is a pharmaceutical company. Co. has developed VIMOVO® with AstraZeneca AB. VIMOVO has been approved by the FDA for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers. Co.'s PA product candidates contain a combination of a proton pump inhibitor and enteric coated aspirin in a single tablet. Co.'s product candidates include PA32540 for the secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, and PA8140, a low dose version of PA32540.
|
Free POZN Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |